High prevalence of dyslipidemia and associated risk factors among rural Chinese adults
Tóm tắt
Dyslipidemia is a key independent modifiable risk factor for Cardiovascular Disease, which is a leading contributor to morbidity and mortality in most developed and developing countries. This study was designed to investigate the current epidemiological features of dyslipidemia among adults in rural China. Between January 2013 and August 2013, we conducted a cross-sectional study involving 11,956 subjects with age ≥35 years in a general Chinese population. Permanent residents of the population were invited to participate in the study and the response rate was at 85.3%. Dyslipidemia was identified based on serum lipids levels following the standards proposed by the National Cholesterol Education Program Adult Treatment Panel III. Multivariate logistic regression analysis was used to evaluate the associated risk factors for dyslipidemia. Within the study population, 16.4% had high TC, 13.8% had low HDL-C, 7.6% had high LDL-C, and 17.3% had high TG concentrations. Prevalence of lipid abnormality (including borderline dyslipidemia and dyslipidemia) was 47.8%, 13.8%, 25.7% and 30.7% for TC, HDL-C, LDL-C and TG, respectively. Detailed analysis indicated that 36.9% of this population had at least one type of dyslipidemia and 64.4% had at least one type of abnormal lipid concentration. Thus, this study observed an alarmingly higher prevalence of lipid abnormality, in a relatively large population, compared to previous studies. Further, we determined that not all of the risk factors studied, including age, gender, hypertension, diabetes mellitus, obesity, smoking, drinking, education level, marital status, and family income, influenced dyslipidemia to the same extent. Our present study, in a population of 11,956 adults in Liaoning Providence, demonstrated a very high prevalence of dyslipidemia, which represented an alarming rise since the publication of our previous study and other similar studies around the world, which report lower levels. We also examined various risk factors for dyslipidemia, many of which are modifiable risk factors for Cardiovascular Disease (CVD), to provide a comprehensive view that will help in designing strategies to slow the rapid spread and promote effective measures to treat dyslipidemia. Our ultimate goal is to prevent the increasing prevalence of lipid abnormality and reduce the burden of CVD in rural China.
Tài liệu tham khảo
Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: global burden of disease study. Lancet. 1997, 349: 1269-1276.
Risk factors for cardiovascular disease in the developing world: a multicentre collaborative study in the International Clinical Epidemiology Network (INCLEN). INCLEN Multicentre Collaborative Group. J Clin Epidemiol. 1992, 45: 841-847.
Jong-wook L: Global health improvement and WHO: shaping the future. Lancet. 2003, 362: 2083-2088.
Reddy KS, Yusuf S: Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998, 97: 596-601.
Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, Zeng Z, Wu Y: Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in china, part i: morbidity and mortality monitoring. Circulation. 2001, 103: 462-468.
Blood pressure, cholesterol, and stroke in eastern Asia: Eastern stroke and coronary heart disease collaborative research group. Lancet. 1998, 352: 1801-1807.
Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD: Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA. 2000, 284: 311-318.
Yusuf S, Reddy S, Ounpuu S, Anand S: Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001, 104: 2746-2753.
, : MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002, 360: 7-22.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, : Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005, 366: 1267-1278.
Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, : Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol. 2004, 44: 720-732.
Toth PP, Potter D, Ming EE: Prevalence of lipid abnormalities in the United States: the national health and nutrition examination survey 2003-2006. J Clin Lipidol. 2012, 6: 325-330.
Zhao WH, Zhang J, Zhai Y, You Y, Man QQ, Wang CR, Li H, Li Y, Yang XG: Blood lipid profile and prevalence of dyslipidemia in Chinese adults. Biomed Environ Sci. 2007, 20: 329-335.
Gu D, Gupta A, Muntner P, Hu S, Duan X, Chen J, Reynolds RF, Whelton PK, He J: Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study Of Cardiovascular Disease in Asia (InterAsia). Circulation. 2005, 112: 658-665.
Wu JY, Duan XY, Li L, Dai F, Li YY, Li XJ, Fan JG: Dyslipidemia in Shanghai, China. Prev Med. 2010, 51: 412-415.
Cai L, Zhang L, Liu A, Li S, Wang P: Prevalence, awareness, treatment, and control of dyslipidemia among adults in Beijing, China. J Atheroscler Thromb. 2012, 19: 159-168.
Wang S, Xu L, Jonas JB, You QS, Wang YX, Yang H: Prevalence and associated factors of dyslipidemia in the adult Chinese population. PLoS One. 2011, 6: e17326-
O’Brien E, Petrie J, Littler W, de Swiet M, Padfield PL, O’Malley K, Jamieson M, Altman D, Bland M, Atkins N: The British Hypertension Society protocol for the evaluation of automated and semi-automated blood pressure measuring devices with special reference to ambulatory systems. J Hypertens. 1990, 8: 607-619.
Kanaya AM, Vittinghoff E, Shlipak MG, Resnick HE, Visser M, Grady D, Barrett-Connor E: Association of total and central obesity with mortality in postmenopausal women with coronary heart disease. Am J Epidemiol. 2003, 158: 1161-1170.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, National Heart L, Blood Institute DE, : The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 Report. JAMA. 2003, 289: 2560-2572.
, : Hypertension control: report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1996, 862: 1-83.
World Health Organ: Diet, nutrition and the prevention of chronic diseases. World Health Organ Tech Rep Ser. 2003, 916: 1-8. 1-149, backcover
Bergman M: Inadequacies of absolute threshold levels for diagnosing prediabetes. Diabetes Metab Res Rev. 2010, 26: 3-6.
, : Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-2497.
Zhang X, Sun Z, Zheng L, Li J, Liu S, Xu C, Li J, Zhao F, Hu D, Sun Y: Prevalence of dyslipidemia and associated factors among the hypertensive rural chinese population. Arch Med Res. 2007, 38: 432-439.
Fuentes R, Uusitalo T, Puska P, Tuomilehto J, Nissinen A: Blood cholesterol level and prevalence of hypercholesterolaemia in developing countries: a review of population-based studies carried out from 1979 to 2002. Eur J Cardiovasc Prev Rehabil. 2003, 10: 411-419.
Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M: Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine. 2008, 34: 36-51.
Wang B, Wei D, Wang C, Zhang J, Pan L, Ma M, Xue F, Wu Z, Shan G: Prevalence of dyslipidemia and associated factors in the Yi farmers and migrants of Southwestern China. Atherosclerosis. 2012, 223: 512-518.
Khader YS, Batieha A, El-Khateeb M, Al Omari M, Ajlouni K: Prevalence of dyslipidemia and its associated factors among Jordanian adults. J Clin Lipidol. 2010, 4: 53-58.
Houston MC, Basile J, Bestermann WH, Egan B, Lackland D, Hawkins RG, Moore MA, Reed J, Rogers P, Wise D, Ferrario CM: Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United States. Am J Med Sci. 2005, 329: 276-291.